Nutriarx

NutriArx is a clinical-stage biotechnology company focused on the development of precision nutrition and medical foods for metabolic health. The company's research centers on the gut-brain axis, specifically identifying nutritional bioactives that modulate the gut microbiome to stimulate the endogenous release of metabolic hormones such as GLP-1 and PYY. Founded by Dr. Mark Heiman, a former CSO at MicroBiome Therapeutics and Eli Lilly scientist, NutriArx aims to provide clinically validated, non-pharmacological interventions for managing type 2 diabetes, obesity, and prediabetes. The company's approach leverages deep expertise in metabolic endocrinology to create targeted nutritional therapies that improve glycemic control and weight management. NutriArx's platform is designed to bridge the gap between traditional nutrition and pharmaceutical intervention through evidence-based medical foods.